FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

BACKGROUND: Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kompier, Lucie C., Lurkin, Irene, van der Aa, Madelon N. M., van Rhijn, Bas W. G., van der Kwast, Theo H., Zwarthoff, Ellen C.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972209/
https://www.ncbi.nlm.nih.gov/pubmed/21072204
http://dx.doi.org/10.1371/journal.pone.0013821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972209/
https://www.ncbi.nlm.nih.gov/pubmed/21072204
http://dx.doi.org/10.1371/journal.pone.0013821

Ejemplares similares